Antitumor agent
AssigneeMitsubishi Tanabe Pharma Corporation
InventorsShinji Miyoshi, Shinsuke Ooike, Kazunori Iwata, Hidemasa Hikawa, Kunio Sugahara
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel antitumor agent containing a compound that inhibits binding between acetylated histone and a bromodomain-containing protein, preferably a thienotriazolodiazepine compound represented by the following formula (I) wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof or a hydrate or solvate as an active ingredient.
Claims13
A method of shrinking, killing, or inhibiting the growth of cancer cells in a mammal, comprising administering an effective amount of
- a thienotriazolodiazepine compound represented by the following formula (I)
- wherein
- R1 is alkyl having a carbon number of 1-4,
- R2 is a hydrogen atom;
- a halogen atom;
- or alkyl having a carbon number of 1-4 optionally substituted by a halogen atom or a hydroxyl group,
- R3 is a halogen atom;
- phenyl optionally substituted by a halogen atom, alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4 or cyano;
- —NR5—(CH2)m—R6 wherein R5 is a hydrogen atom or alkyl having a carbon number of 1-4, m is an integer of 0-4, and R6 is phenyl or pyridyl optionally substituted by a halogen atom;
- or —NR7—CO—(CH2)n—R8 wherein R7 is a hydrogen atom or alkyl having a carbon number of 1-4, n is an integer of 0-2, and R8 is phenyl or pyridyl optionally substituted by a halogen atom, and
- R4 is —(CH2)a—CO—NH—R9 wherein a is an integer of 1-4, and R9 is alkyl having a carbon number of 1-4;
- hydroxyalkyl having a carbon number of 1-4;
- alkoxy having a carbon number of 1-4;
- or phenyl or pyridyl optionally substituted by alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4, amino or a hydroxyl group) or —(CH2)b—COOR10 wherein b is an integer of 1-4, and R10 is alkyl having a carbon number of 1-4,
- or a pharmaceutically acceptable salt thereof or (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide dihydrate
- to a mammal with cancer cells, wherein the cancer is hematologic cancer, myeloma, liver cancer, ovarian cancer, prostate cancer, lung cancer, osteosarcoma, or colorectal cancer, whereupon the cancer cells are shrunk or killed in the mammal or the growth of the cancer cells is inhibited in the mammal.
A method of shrinking or killing of hematologic cancer cells or inhibiting the growth of hematologic cancer cells in a mammal, comprising administering an effective amount of (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide or a dihydrate thereof to a mammal with hematologic cancer cells, whereupon the hematologic cancer cells are shrunk or killed in the mammal or the growth of the hematologic cancer cells is inhibited in the mammal.
A method of shrinking or killing of lymphoma cells or inhibiting the growth of lymphoma cells in a mammal, comprising administering an effective amount of (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,24-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide or a dihydrate thereof to a mammal with lymphoma cells, whereupon the lymphoma cells are shrunk or killed in the mammal or the growth of the lymphoma cells is inhibited in the mammal.
A method of shrinking or killing of leukemia cells or inhibiting the growth of leukemia cells in a mammal, comprising administering an effective amount of (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide or a dihydrate thereof to a mammal with leukemia cells, whereupon the leukemia cells are shrunk or killed in the mammal or the growth of the leukemia cells is inhibited in the mammal.
A method of shrinking or killing of myeloma cells or inhibiting the growth of myeloma cells in a mammal, comprising administering an effective amount of (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide or a dihydrate thereof to a mammal with myeloma cells, whereupon the myeloma cells are shrunk or killed in the mammal or the growth of the myeloma cells is inhibited in the mammal.
A method of shrinking or killing of lung cancer cells or inhibiting the growth of lung cancer cells in a mammal, comprising administering an effective amount of (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide or a dihydrate thereof to a mammal with lung cancer cells, whereupon the lung cancer cells are shrunk or killed in the mammal or the growth of the lung cancer cells is inhibited in the mammal.
Dependencies are inferred from the claim text.